CClinicalTrials.gg
CompletedNCT03690648CHIKGENEUpdated Aug 30, 2022

Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya

An observational study in Chikungunya Fever, sponsored by Centre Hospitalier Universitaire de la Réunion. Completed at 1 site in Réunion. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-30.

Sponsored by Centre Hospitalier Universitaire de la Réunion · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
600
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Chikungunya virus (CHIKV) infection has become a threat to public health worldwide. Reunion Island, due to the 2005-2006 epidemic, has acquired unique expertise and remains at the forefront of global research on this disease. The idea of genetic determinism of the clinical expression of infectious diseases has been supported by many epidemiological arguments over the past fifty years. The identification of genetic variants, associated with a disease, often allows a better understanding of the molecular mechanisms involved with consequent significant benefits such as the development of specific biomarkers for new preventive (vaccination) and / or therapeutic (drug design) approaches. In the absence of well-documented hypotheses about the genes potentially involved in the occurrence or evolution of a disease, genome-wide association studies (GWAS), whole genome, of nucleotide polymorphisms (SNPs) and the principle of linkage disequilibrium, under the commonly accepted hypothesis that the expression of a common disease is based on a small number of alleles commonly found in the population (frequency of minor allele greater than 1-5%), have become a method of choice, free of hypothesis, to specify the part of heritability of a complex disease and to identify its genetic determinants. Several epidemiological arguments support a significant proportion of genetic determinism in the explanation of the evolutionary pattern of Chikungunya, whose proportion of chronic forms can reach 40-60% in population-based studies conducted in the two years following an epidemic:

  • There are few risk factors associated with chronic forms and these appear to be unclear (age, comorbidities with several elements of the metabolic syndrome) or inconsistent (immune burden) in population studies;
  • The incidence of severe or atypical forms is rare in the order of 1% of infections;
  • In contrast to the acute phase (J1-J21) for which there seems to be a role of the viral load intensity and a consensual pro-inflammatory immune signature according to a recent meta-analysis]; The role of the intensity of the viral load in the pathogenesis of chronic arthralgia (> J90) and their immune signature remain to be determined, the latter being rather nonspecific, according to studies conducted in Reunion, Italy or Singapore.

These elements justify the interest of a GWAS in the Chikungunya to identify new avenues and mechanistic hypotheses likely to explain the chronic arthralgia characteristic of the disease.

02

Conditions studied

  • Chikungunya Fever
03

In context

Chikungunya Fever

84 studies on the registry are indexed under Chikungunya Fever; 18 are open to participants now.

This study's enrollment of 600 is close to the median of 570 across 25 observational studies indexed under Chikungunya Fever.

Browse Chikungunya Fever studies →

Lead sponsor

Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 137 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subject with a serological status known for Chikungunya virus for the period between March 1st, 2005 and December 31st, 2006 (epidemic period in reunion Island).

Inclusion criteria

  • -Subject of the seroprevalence survey or neighbor living in the same neighborhood likely to confirm an exposure status or known;
  • Exposure status established by specific IgG serology, collected between March 1st, 2005 and December 31st, 2006;
  • Affiliated to a social security scheme;
  • Age between 18 and 75 years old;
  • Paternal and maternal 1st and 2nd degree ascendants (parents and grandparents) and at least 3 generations of the family present on the island (grandparents born on the island of Réunion);
  • Able to spit

Exclusion criteria

Exclusion Criteria:

  • Exposure status unknown;
  • Absence of social security;
  • Age \<18 years and> 75 years;
  • Physical inability to spit;
  • Pregnant women;
  • Protected person (tutorship or curatorship).
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
600 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Saliva collection

    * Clinical examination; * Quality of life survey; * Saliva collection for genetical analysis

    Other: Quality of life survey · Genetic: Saliva collection

  • Saliva and Blood collection

    * Clinical examination; * Quality of life survey; * Saliva and blood collection for genetical analysis

    Other: Quality of life survey · Genetic: Saliva collection · Genetic: Blood collection

Interventions

  • OtherQuality of life survey

    Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD

  • GeneticSaliva collection

    Collection of 20 ml of saliva with a kit of saliva collection

  • GeneticBlood collection

    Collection of 20 ml of blood with kit of blood collection

06

What researchers measure

Primary outcomes

  1. identify by a genome-wide association study the genetic factors associated with the evolutionary profile of Chikungunya

    to determine if certain genetic profiles may be predictive of progression to asymptomatic or acute disease, or to the chronic character of the manifestations of the disease

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • CHU de La Réunion
    Saint-Pierre, 97410, Réunion
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03690648
Lead sponsor
Centre Hospitalier Universitaire de la Réunion
Collaborators
Conservatoire national des Arts et Métiers
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Aug 1, 2018
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Aug 30, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion